Brief: Anebulo Pharmaceuticals Announces Positive Topline Data For Aneb-001 From A Phase 2 Clinical Trial For Acute Cannabinoid Intoxication
05/07/2022 11:08
July 5 (Reuters) - Anebulo Pharmaceuticals Inc ANEB.O :
* ANEBULO PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA
FOR
ANEB-001 FROM A PHASE 2 CLINICAL TRIAL FOR ACUTE CANNABINOID
INTOXICATION
* STUDY MET PRIMARY ENDPOINT VAS FEELING HIGH (P < 0.0001)
* SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR
ANEB-001 TO INITIATE U.S. TRIALS IS ANTICIPATED BY END OF 2022
Source text for Eikon: ID:nBwbvtDW5a
Further company coverage: ANEB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anebulo Pharmaceuticals
See all newsAdvisory: Dated alert on Anebulo Pharmaceuticals' voluntary delisting from Nasdaq withdrawn
Anebulo Pharmaceuticals Q2 net loss narrows
Brief: Anebulo Pharmaceuticals Announces Intention To Voluntarily Delist From Nasdaq And Deregister With SEC
Anebulo Pharmaceuticals posts Q1 net loss
Brief: Anebulo Pharmaceuticals Reports Fourth Quarter And Fiscal Year 2025 Financial Results